Lucrative ERC grants for five LMU researchers
Grant and Award Announcement
Updates every hour. Last Updated: 11-Dec-2025 06:11 ET (11-Dec-2025 11:11 GMT/UTC)
Five LMU researchers have been awarded Consolidator Grants by the European Research Council. Their projects deal with climate change, strokes, quantum physics, mitochondria, and cancer diagnosis.
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial.
Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart Mipitecan (LY4170156), a Novel ADC Targeting Folate Receptor Alpha (FRα), in Recurrent Ovarian Cancer
The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3133, a pivotal Phase 3 clinical trial titled FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. The study is sponsored by Eli Lilly and Company and conducted in collaboration with The GOG Foundation, Inc.
MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero off-target activity. By selectively removing wild-type DNA before sequencing, it boosts true mutant signals up to tens of times and enables detection as low as ~0.005% VAF. The technique improves MRD monitoring and early-stage cancer detection while avoiding the need for costly ultra-deep sequencing.
A new Curtin University study has found people diagnosed with sarcoma – a cancer disproportionately affecting teenagers and young adults – are being left without the resources they urgently need.
-Study shows T-cell redirecting therapy can safely be monitored at home, potentially eliminating routine hospitalization after CAR-T and BiTE treatments.
-Outpatient observation cut hospital stays dramatically, with no adverse safety events reported.
-This approach reduces time patients spend away from their families while also freeing up inpatient beds and cutting healthcare costs.